全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Resolution of Praziquantel

DOI: 10.1371/journal.pntd.0001260

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Praziquantel remains the drug of choice for the worldwide treatment and control of schistosomiasis. The drug is synthesized and administered as a racemate. Use of the pure active enantiomer would be desirable since the inactive enantiomer is associated with side effects and is responsible for the extremely bitter taste of the pill. Methodology/Principal Findings We have identified two resolution approaches toward the production of praziquantel as a single enantiomer. One approach starts with commercially available praziquantel and involves a hydrolysis to an intermediate amine, which is resolved with a derivative of tartaric acid. This method was discovered through an open collaboration on the internet. The second method, identified by a contract research organisation, employs a different intermediate that may be resolved with tartaric acid itself. Conclusions/Significance Both resolution procedures identified show promise for the large-scale, economically viable production of praziquantel as a single enantiomer for a low price. Additionally, they may be employed by laboratories for the production of smaller amounts of enantiopure drug for research purposes that should be useful in, for example, elucidation of the drug's mechanism of action.

 References

[1]  Ross AGP, Bartley PB, Sleigh AC, Olds GR, Li Y, et al. (2002) Schistosomiasis. N Engl J Med 346: 1212–1220. (DOI: 10.1056/NEJMra012396). doi: 10.1056/NEJMra012396
[2]  Chitsulo L, Engels D, Montresor A, Savioli L (2000) The global status of schistosomiasis and its control. Acta Trop 77: 41–51. (DOI: 10.1016/S0001-706X(00)00122-4). doi: 10.1016/S0001-706X(00)00122-4
[3]  King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365: 1561–1569. (DOI: 10.1016/S0140-6736(05)66457-4). doi: 10.1016/S0140-6736(05)66457-4
[4]  Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11: 433–439. (DOI: 10.1016/j.cbpa.2007.05.031). doi: 10.1016/j.cbpa.2007.05.031
[5]  Caffrey CR, Williams DL, Todd MH, Nelson DL, Keiser J, et al. (2009) Chemotherapeutic development strategies for schistosomiasis. In: Selzer PM, editor. Antiparasitic and antibacterial drug discovery from molecular targets to drug candidates. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA. (DOI: 10.1002/9783527626816.ch16).
[6]  Fenwick A, Savioli L, Engels D, Bergquist R, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development. Schistosomiasis Trends Parasitol 19: 509–515. (DOI: 10.1016/j.pt.2003.09.005). doi: 10.1016/j.pt.2003.09.005
[7]  Andrews P, Thomas H, Pohlke R, Seubert J (1983) Praziquantel. Med Res Rev 3: 147–200. (DOI: 10.1002/med.2610030204). doi: 10.1002/med.2610030204
[8]  Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659–667. (DOI: 10.1097/QCO.0b013e328318978f). doi: 10.1097/QCO.0b013e328318978f
[9]  Schistosomiasis Control Initiative Website. Available: http://www3.imperial.ac.uk/schisto. Accessed 2011 Jun 27.
[10]  Hotez PJ, Engels D, Fenwick A, Savioli L (2010) Africa is desperate for praziquantel. Lancet 376: 496–498. (DOI: 10.1016/S0140-6736(10)60879-3). doi: 10.1016/S0140-6736(10)60879-3
[11]  Fallon PG, Doenhoff MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 51: 83–88. (http://www.ajtmh.org/cgi/content/abstrac？t/51/1/83).
[12]  Liang YS, Wang W, Dai JR, Li HJ, Tao YH, et al. (2010) Susceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni. J Helminthol 84: 202–207. (DOI: 10.1017/S0022149X0999054X). doi: 10.1017/S0022149X0999054X
[13]  Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, et al. (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Neglect Trop D 3: e504. (DOI: 10.1371/journal.pntd.0000504). doi: 10.1371/journal.pntd.0000504
[14]  Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? T Roy Soc Trop Med H 96: 465–469. (DOI: 10.1016/S0035-9203(02)90405-0).
[15]  Liang YS, Coles GC, Doenhoff MJ, Southgate VR (2001) In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 31: 1227–1235. (DOI: 10.1016/S0020-7519(01)00246-6). doi: 10.1016/S0020-7519(01)00246-6
[16]  Dong Y, Chollet J, Vargas M, Mansour NR, Bickle B, et al. (2010) Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg Med Chem Lett 20: 2481–2484. (DOI: 10.1016/j.bmcl.2010.03.001). doi: 10.1016/j.bmcl.2010.03.001
[17]  Laurent SAL, Boissier J, Coslédan F, Gornitzka H, Robert A, et al. (2008) Synthesis of “trioxaquantel”？ derivatives as potential new antischistosomal drugs. Eur J Org Chem 895-913: (DOI: 10.1002/ejoc.200700975). doi: 10.1002/ejoc.200700975
[18]  Ronketti FE, Ramana AV, Chao-Ming X, Pica-Mattoccia L, Cioli D, et al. (2007) Praziquantel analogues. I. Modification of the aromatic ring. Bioorg Med Chem Lett 17: 4154–4157. (DOI: 10.1016/j.bmcl.2007.05.063). doi: 10.1016/j.bmcl.2007.05.063
[19]  Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP (2008) Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 14: 407–412. (DOI: 10.1038/nm1737). doi: 10.1038/nm1737
[20]  Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, et al. (2008) Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop D 2(1): e127. (DOI: 10.1371/journal.pntd.0000127). doi: 10.1371/journal.pntd.0000127
[21]  Xiao SH, Catto BA (1989) Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis 159: 589–592. (http://www.jstor.org/stable/30137494).
[22]  Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, et al. (1991) Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of Schistosomiasis japonica.. Am J Trop Med Hyg 45: 345–349. (http://www.ajtmh.org/cgi/content/abstrac？t/45/3/345).
[23]  Liu Y, Qian M, Wang X, Jia J, Wang Q, et al. (1986) Comparative efficacy of praziquantel and its optic isomers in experimental therapy of Schistosomiasis japonica in rabbits. Chin Medical J 99: 935–940.
[24]  Tanaka M, Ohmae H, Utsunomiya H, Nara T, Irie Y, et al. (1989) A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice. Am J Trop Med Hyg 41: 198–203.
[25]  Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, et al. (2009) Taste, A new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop D 3: e357. (DOI: 10.1371/journal.pntd.0000357). doi: 10.1371/journal.pntd.0000357
[26]  Parker M, Allen T, Hastings J (2008) Resisting control of neglected tropical diseases: dilemmas in the mass treatment of schistosomiasis and soil-transmitted helminths in north-west Uganda. J Biosoc Sci 40: 161–181. (DOI: 10.1017/S0021932007002301). doi: 10.1017/S0021932007002301
[27]  Fleming FM, Fenwick A, Tukahebwa EM, Lubanga RG, Namwangye H, et al. (2009) Process evaluation of schistosomiasis control in Uganda, 2003 to 2006: perceptions, attitudes and constraints of a national control programme. Parasitology 136: 1759–1769. (DOI: 10.1017/S0031182009990709). doi: 10.1017/S0031182009990709
[28]  Drug Development and Evaluation for Helminths and Other Neglected Tropical Diseases (2007) Business Plan 2008-2013, WHO/TDR. Available: http://apps.who.int/tdr/svc/publications？/about-tdr/business-plans/bl6-business-p？lan-2008-2013. Accessed 2011 Jun 27.
[29]  Aragon AD, Imani RA, Blackburn VR, Cupit PM, Melman SD, et al. (2009) Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasit 164: 57–65. and references cited therein. (DOI: 10.1016/j.molbiopara.2008.11.007).
[30]  Roszkowski P, Maurin JK, Czarnocki Z (2006) Enantioselective synthesis of (R)-(–)-praziquantel (PZQ). Tetrahedron: Asymmetry 17: 1415–1419. (DOI: 10.1016/j.tetasy.2006.04.023). doi: 10.1016/j.tetasy.2006.04.023
[31]  Ma C, Zhang QF, Tan YB, Wang L (2004) Total synthesis of (-)-praziquantel: an anthelmintic drug. J Chem Res 186–187. (DOI: 10.3184/0308234041640564). doi: 10.3184/0308234041640564
[32]  Pohlke R, Loebich F, Seubert J, Thomas H, Andrews P (1976) Pyrazinoisoquinolines as anthelmintic agents. US Patent 3,993,760 (German patent (1973) 2,331,713) (http://www.google.com/patents/about?id=q？rs1AAAAEBAJ&dq=3993760).
[33]  Seubert J (1982) Process for preparing (1-acylaminomethyl)-1,2,3,4-tetrahydrois？oquinolines. US Patent 4,362,875 (German patent (1975) 2,504,250) (http://www.google.com/patents/about?id=7？EE4AAAAEBAJ&dq=4362875).
[34]  Seubert J, Thomas H, Andrews P (1977) Attempt at asymmetric hydrogenation of intermediate enamide: 2-acyl-4-oxo-pyrazino-isoquinoline derivatives and process for the preparation thereof. US Patent 4,001,411 (German patent (1973) 2,362,539) (http://www.google.com/patents/about?id=x？xEtAAAAEBAJ&dq=4001411).
[35]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/276#？comment-596. Accessed 2011 Jun 27.
[36]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/315. Accessed 2011 Jun 27.
[37]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/313#？comment-540. Accessed 2011 Jun 27.
[38]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/296. Accessed 2011 Jun 27.
[39]  Kim JH, Lee YS, Park H, Kim CS (1998) Formation of pyrazinoisoquinoline ring system by the tandem amidoalkylation and N-acyliminium ion cyclization: an efficient synthesis of praziquantel. Tetrahedron 54: 7395–7400. (DOI: 10.1016/S0040-4020(98)00401-3). doi: 10.1016/s0040-4020(98)00401-3
[40]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？696. Accessed 2011 Jun 27.
[41]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？717. Accessed 2011 Jun 27.
[42]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？742. Accessed 2011 Jun 27.
[43]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？1279. Accessed 2011 Jun 27.
[44]  Kozhushkov SI, Yufit DS, de Meijere A (2005) Convenient and inexpensive synthesis of (1R,2R)-trans-1-amino-6-nitroindan-2-ol. Adv Synth Catal 347: 255–265. (DOI: 10.1002/adsc.200404296). doi: 10.1002/adsc.200404296
[45]  Daugs ED, Evans JC, Flemming HW, Hilpert THE, Koek JN, et al. (2002) Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fl？uorophenyl)ethyl]-4-piperidinemethanol. US Patent Application US 2002/0151717 (A1).
[46]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？1185. Accessed 2011 Jun 27.
[47]  Rabe P (1932) über die reduktion der China-ketone zu China-alkoholen und über die sterische umlagerung von China-alkaloiden. Stereochemische forschungen. II. Liebigs Ann Chem 492: 242–266. (DOI: 10.1002/jlac.19324920112). doi: 10.1002/jlac.19324920112
[48]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？1309. Accessed 2011 Jun 27.
[49]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？1468. Accessed 2011 Jun 27.
[50]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/333. Accessed 2011 Jun 27.
[51]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/schisto/c？ommunity. Accessed 2011 Jun 27.
[52]  OurExperiment.org website. Available: http://www.ourexperiment.org/, (Accessed 2011 Jun 27).
[53]  Woelfle M, Olliaro P, Todd MH (2011) Open Science is a Research Accelerator. Nature Chemistry 3: doi:10.1038/nchem.1149.
[54]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/202. Accessed 2011 Jun 27.
[55]  Federsel HJ (2010) Asymmetric catalysis on industrial scale. Blaser HU, editor. Weinheim: Wiley-VCH.
[56]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/323. Accessed 2011 Jun 27.
[57]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/205. Accessed 2011 Jun 27. Raw data to date at the OurExperiment.org website. Available: http://www.ourexperiment.org/racemic_pzq. Accessed 2011 Jun 27.
[58]  Taylor MS, Jacobsen EN (2004) Highly enantioselective catalytic acyl-Pictet-Spengler reactions. J Am Chem Soc 126: 10558–10559. (DOI: 10.1021/ja046259p). doi: 10.1021/ja046259p
[59]  Cao H, Liu H, Doemling A (2010) Efficient multicomponent reaction synthesis of the schistosomiasis drug praziquantel. Chem Eur J 16: 12296–12298. (DOI: 10.1002/chem.201002046). doi: 10.1002/chem.201002046
[60]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/312. Accessed 2011 Jun 27.
[61]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/305. Accessed 2011 Jun 27.
[62]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/313. Accessed 2011 Jun 27.
[63]  The Synaptic Leap website. Available: http://www.thesynapticleap.org/node/305#？comment-595. Accessed 2011 Jun 27.
[64]  OurExperiment.org website. Available: http://www.ourexperiment.org/racres_pzq/？641. Accessed 2011 Jun 27.
[65]  Kellogg RM, Nieuwenhuijzen JW, Pouwer K, Vries TR, Broxterman QB, et al. (2003) Dutch Resolution: Separation of Enantiomers with Families of Resolving Agents. A Status Report. Synthesis 1626–1638. (DOI: 10.1055/s-2003-40508). doi: 10.1055/s-2003-40508
[66]  Vries T, Wynberg H, van Echten E, Koek J, tenHoeve W, et al. (1998) The Family Approach to the Resolution of Racemates. Angew Chem Int Ed 37: 2349–2354. (DOI: 10.1002/(SICI)1521-3773(19980918)37:17<2？349::AID-ANIE2349>3.0.CO;2-I).
[67]  Horeau A (1969) Interactions d'enantiomeres en solution ; influence sur le pouvoir rotatoire : Purete optique et purete enantiomerique. Tetrahedron Lett 10: 3121–3124. DOI:10.1016/S0040-4039(01)88364-7).
[68]  OurExperiment.org website. Available: http://www.ourexperiment.org/rac_pza. Accessed 2011 June 27.
[69]  The OurExperiment.org website. Available: http://pzq.ourexperiment.org/. Accessed 2011 June 27.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133